Clinical Trial Update: Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of pembrolizumab plus axitinib for renal cell carcinoma with inferior vena cava tumor thrombus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inferior Vena Cava Thrombosis
• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Renal Cancer, Kidney Cancer | Phase 2 | Status: RECRUITING